XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue Recognition | 6 Months Ended
--- | ---
Jun. 30, 2018
Revenue from Contract with Customer [Abstract] |
Revenue Recognition | Revenue Recognition On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historical accounting under Topic 605. For additional details about Topic 606, refer to Note 3 above. The following table summarizes changes in the Company’s contract assets and liabilities for the six months ended June 30, 2018:
| Balance at January 1, 2018 |  | Additions |  | Deductions |  | Balance at June 30, 2018
Contract assets |  |  |  |  |  |  |
Accounts receivable from MedImmune | $ | 1,693,530 |  |  | $ | 2,541,901 |  |  | $ | (3,142,901 | ) |  | $ | 1,092,530 |
Contract liabilities |  |  |  |  |  |  |
Deferred revenue - MedImmune | 1,145,500 |  |  | 582,500 |  |  | (882,000 | ) |  | 846,000 |
Deferred revenue - ApolloBio | — |  |  | 23,000,000 |  |  | (23,000,000 | ) |  | — |
Deferred revenue - Other | $ | 271,894 |  |  | $ | — |  |  | $ | (125,251 | ) |  | $ | 146,643 |
During the three and six months ended June 30, 2018, the Company recognized total revenue under collaborative research and development and other agreements of $23.0 million from ApolloBio; $1.4 million and $2.7 million, respectively, from MedImmune; $32,000 and $150,000, respectively, from its affiliated entity GeneOne Life Science Inc. ("GeneOne"); and $31,000 and $153,000, respectively, from various other contracts. Of the total revenue recognized during the three and six months ended June 30, 2018, $354,000 and $1.0 million, respectively, was in deferred revenue, as of December 31, 2017. All revenues recognized during the three and six months ended June 30, 2018 are attributed to the United States.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration